Which validation documents and risk assessments are required for GMP inspections?
No blanket "documentation package" is prescribed for GMP inspections. What is expected is rather a coherent, risk-based and lifecycle-oriented system of evidence demonstrating that plants, processes, cleaning procedures, computerised systems and test methods are suitable for their intended purpose and remain permanently under control. Depending on product, market and authority, the governing references are in particular the EU GMP Guide with Annex 15 and Annex 11, the ICH guidelines Q8, Q9 and Q10, and, for the US market, 21 CFR Part 211 and Part 11 among others.
The central framework document is usually the validation master plan. It describes the scope of the qualification and validation system, responsibilities, procedures, priorities and the links to SOPs, change control, deviation management, CAPA and periodic reviews. What is decisive is that the individual activities – from requirement through to release – can be traced back to this system in a comprehensible way.
Qualification documentation is required for GMP-relevant plants, utilities and, where applicable, automated systems. Typical phases are design qualification, installation qualification, operational qualification and performance qualification. The documents must contain requirements, acceptance criteria, test results, deviations, assessments and formal releases. What matters is not the number of documents but the traceable demonstration that the plant functions reproducibly within the intended operating range.
Process validation must demonstrate that a manufacturing process permanently delivers products within the specified quality requirements. This includes the definition of critical quality attributes and critical process parameters, a risk-based validation plan, documented validation runs and the statistical evaluation of the results. A rigid requirement of three validation batches is no longer regarded as universally applicable today; scope and sample size must be justified scientifically and on a risk basis. The validation status is monitored by continued process verification with trend analyses and an assessment of the state of control.
For cleaning processes, a cleaning validation plan, worst-case considerations, justified acceptance limits and validation protocols and reports are required. Acceptance limits for active ingredient residues are today frequently derived toxicologically, for example on the basis of PDE or HBEL concepts. Recovery studies, the suitability of the analytical method and, where applicable, microbiological aspects must be taken into account. Which requirements apply in an individual case depends among other things on the type of product, the manufacturing environment and the risk of cross-contamination.
Computerised GMP-relevant systems must be qualified or validated across their entire lifecycle. Typically required are a requirements specification, a documented risk analysis, test plans and protocols, traceability between requirements and tests, and a validation report. Particularly critical are data integrity, user and permission concepts, audit trails, electronic signatures, data backup, change management and periodic reviews. Annex 11 expressly requires that validation documentation and reports cover the relevant lifecycle phases and that the scope is justified on the basis of a risk assessment.
Analytical methods must likewise be suitable for their intended purpose. Depending on the method and application, specificity, precision, accuracy, linearity, working range, robustness and the limits of detection and quantification are to be investigated, for example. Added to these are system suitability tests and, where laboratories or sites change, documented method transfers.
Risk assessments connect all these elements. They serve to evaluate critical quality attributes, process parameters, plant functions, data integrity risks, cross-contamination risks and control measures systematically. Methods such as FMEA, HACCP or toxicologically based risk analyses may be suitable for this. Of particular relevance to inspections is the visible chain from risk assessment through the validation scope derived from it, the control strategy, deviation management, CAPA and change control.
All documents must comply with the principles of good documentation practice: they must be attributable, legible, contemporaneous, original and accurate, and must remain complete, consistent, enduring and available when required. Alongside the validation dossiers, inspectors frequently also examine the site master file, SOPs, training records, maintenance and calibration documents, change control procedures, deviations, CAPA trends and document control.
What is decisive for a GMP inspection is therefore not the isolated existence of individual DQ, IQ, OQ or PQ documents. What is required is a consistent and risk-based chain of evidence – from requirements and risks through qualification and validation to the continuous monitoring of the controlled state.
How amixon® supports FAT/SAT and the qualification (DQ/IQ/OQ/PQ) of pharmaceutical mixing plants
From the URS to a qualifiable plant
Production plants for powdered active ingredients stand or fall with the machines that mix, dry, agglomerate or react the substances. Errors at this point can hardly be compensated for later in the process. amixon® therefore designs every apparatus as a one-off on the basis of the operator's User Requirement Specification (URS) and manufactures it at its own works in Paderborn. Quality control remains entirely in-house and specifications are traceable and demonstrable down to component level – material certificates, surface finishes and welding documentation.
DQ, IQ, OQ – with amixon® support
amixon® supports the operator with design qualification (DQ), installation qualification (IQ) and operational qualification (OQ). The documentation and the technical execution follow, on request, the relevant requirements of EU GMP and FDA guidelines. The plant is integrated in accordance with the operator's validation concept – from the URS through specifications and tests to commissioning. Requirements for electronic records and evaluations (e.g. audit trail, user administration, data security) are implemented project-specifically in the automation, including PLC programs, optional ERP connection and gap-free batch documentation.
FAT and SAT
The factory acceptance test (FAT) takes place at the Paderborn works on the actual apparatus – on the basis of the agreed test points from the URS and specification. Assembly, commissioning and the site acceptance test (SAT) are carried out by an experienced amixon® team in close coordination with the operator's specialist departments. The protocols and measurement results produced in the process feed into the operator's IQ/OQ documentation. Performance qualification (PQ) with product is the operator's responsibility. On request, amixon® provides the process parameters determined in the pilot plant with the original product as a secured starting basis.
The design foundation: hygienic design
GMP-compliant hygienic design is the prerequisite for successful qualification. amixon® relies on dead-space-free, crevice-free welded mixing chambers, top-mounted mixing tools with no lower shaft passage, generously dimensioned Clever-Cut® inspection doors and ergonomic accessibility to all product-contact surfaces. Validatable dry, CIP and WIP cleaning as well as sterile versions to the relevant hygiene standards (e.g. EHEDG, 3-A) are designed and documented project-specifically.
Verification in the amixon® pilot plant
Proof under realistic conditions comes before the investment. In the amixon® pilot plant at the Paderborn headquarters, 35 test units in various sizes are available. Further pilot plants are located in Japan, India, Thailand, China, South Korea and the USA. The trials are carried out with original products, real fill levels and batch sizes and within the intended temperature and pressure range. Mixing quality, product protection, energy demand, cleanability and reproducibility are assessed. The results are evaluated and documented together with amixon® specialists – as a sound basis for the decision that markedly reduces technical and economic risks ahead of the investment.